These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21690427)

  • 1. Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections.
    Holt SL; Drew RH
    Am J Health Syst Pharm; 2011 Jul; 68(13):1207-20. PubMed ID: 21690427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.
    Kofla G; Ruhnke M
    Eur J Med Res; 2011 Apr; 16(4):159-66. PubMed ID: 21486730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
    Xu G; Zhu L; Liao S; Ge T; Yang J
    Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    Ou HT; Lee TY; Chen YC; Charbonneau C
    BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?
    Tapısız A
    Expert Rev Anti Infect Ther; 2011 Mar; 9(3):339-46. PubMed ID: 21417873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.
    Glöckner A
    Eur J Med Res; 2011 Apr; 16(4):167-79. PubMed ID: 21486731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The echinocandins.
    Cappelletty D; Eiselstein-McKitrick K
    Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The echinocandins: three useful choices or three too many?
    Bal AM
    Int J Antimicrob Agents; 2010 Jan; 35(1):13-8. PubMed ID: 19942413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caspofungin therapy in immunocompromised children and neonates.
    Somer A; Törün SH; Salman N
    Expert Rev Anti Infect Ther; 2011 Mar; 9(3):347-55. PubMed ID: 21417874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Echinocandins in children].
    Leverger G; Le Guyader N
    Arch Pediatr; 2011 May; 18 Suppl 1():S33-41. PubMed ID: 21596285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Echinocandins in the management of invasive fungal infections, Part 2.
    Morris MI; Villmann M
    Am J Health Syst Pharm; 2006 Oct; 63(19):1813-20. PubMed ID: 16990627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
    Wilke M
    Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of New Strategies for Echinocandins: Progress in Translational Research.
    Walsh TJ; Azie N; Andes DR
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S601-3. PubMed ID: 26567276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspofungin acetate for treatment of invasive fungal infections.
    Pacetti SA; Gelone SP
    Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Echinocandins: The Expanding Antifungal Armamentarium.
    Aguilar-Zapata D; Petraitiene R; Petraitis V
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S604-11. PubMed ID: 26567277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi].
    Salavert-Lletí M; Zaragoza-Crespo R
    Rev Iberoam Micol; 2009 Mar; 26(1):81-9. PubMed ID: 19463284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.